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It has already been  shown  (1,  2)  that  long-surviving, passively enhanced  (AS  × 
AUG)F1 rat  kidneys originally transplanted  to AS strain recipients are not  rejected 
acutely if retransferred to a normal second AS recipients. This contrasts with the fate 
of normal  (AS  ×  AUG)F1  primary kidney allografts  transplanted  to AS  recipients 
that are always rejected within  12 d, and suggests that in this strain combination the 
retransplanted  kidneys have greatly reduced  alloimmunogenicity as compared with 
a  primary allograft. Previous work in this laboratory (3)  has provided evidence that 
the reduction in immunogenicity is due to a loss of donor strain bone marrow-derived 
passenger  cells  from  the  kidney  during  its  residence  in  the  first  recipient.  These 
experiments also suggested that within the passenger cell component of a kidney graft 
a specialized subpopulation,  the dendritic cells, play a  pivotal role in conferring the 
strong primary alloimmunogenicity associated with primary kidney allografts. As few 
as 5 X  104 donor strain dendritic cells injected into the secondary recipient at the time 
of receiving a retransplanted kidney allograft led to acute graft destruction, whereas 
5 ×  l0  s splenic adherent cells or 5 X  106 T  or B lymphocytes had no effect on graft 
acceptance. If this passenger cell hypothesis is correct, changing the genotype of the 
passenger cells  in  the  long-surviving enhanced  allograft  back to  that  of the  donor 
strain should restore its immunogenicity. Results are presented here of kidney retrans- 
plantation  after the induction  of donor strain bone marrow chimerism in the inter- 
mediate recipient. 
In  the  previous paper,  we proposed  the  hypothesis  that  class  II alloantigen  can 
immunize  via  two  routes  (3);  the  significance  of the  class  II  MHS-incompatible 
dendritic cell lies in its capacity to activate directly helper T  lymphocytes (TH)1 of the 
recipient  (route  1). Alloantigen, including class II MHS incompatibility, present on 
all  cells other than  dendritic  cells  (and  other specialized APC),  is  treated  like any 
conventional protein antigen and requires to be picked up, processed, and presented 
to TH by the recipient's own APC (route 2). Route 2 is likely to be a much less efficient 
mechanism of alloimmunization because the density of the processed alloantigen  in 
association with class II MHS molecules of the recipient's APC is likely to be so much 
lower than the class II alloantigen molecules expressed on the allogeneic APC involved 
1  Abbreviations used in this paper:  APC,  antigen-presenting cells; MHS, major histocompatibility  system; 
TH, T helper cells. 
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in route 1 immunization. The hypothesis is based on the assumption that the trigger 
that activates T~ is altered self class II MHS molecules on APC and that allogeneic 
class II MHS molecules are "seen" by the Tn as altered self. 
According  to  our  hypothesis,  the  retransplanted  kidney,  depleted  of  all  bone 
marrow-derived cells,  is confined to  immunizing via route  2,  and  this  explains its 
reduced immunogenicity. However, there is some strain dependent variation in the 
survival of retransplanted rat kidney allografts, and in certain donor recipient strain 
combinations destruction of the retransferred kidney does occur (4)  (possible reasons 
for this variation will be mentioned in the discussion). We predicted that the rejection 
response to such a  kidney, immunizing exclusively via route 2, would be much more 
easily  suppressed  than  the  rejection  of a  primary  graft  between  the  same  strains 
immunizing via  routes  1  and  2.  Experiments  are  described  here  using  a  strain 
combination in which the retransplanted kidney allograft is rejected; comparison is 
then made between the dosage of pharmacological immunosuppression required to 
maintain prolonged survival and  function of a  primary  graft  and  that  needed  to 
produce the same effect in the retransplanted kidney depleted of highly immunogenic 
allogeneic passenger cells. 
Materials and Methods 
Animals.  We used the following inbred strains or hybrids derived from them: AS (RTIA  1) 
and AUG  (RTIAC).  The parental strains were bred at  the  National Institute for  Medical 
Research, Mill Hill, and hybrids from them were bred in the experimental animal unit at this 
institution. All rats were maintained here. 
Kidney  Transplants  and Retransplants.  These were performed by conventional microsurgical 
technique, as previously described (1). Animals were inspected at regular intervals for survival 
and bled for serum urea estimations on days 7,  10,  14,  21, and 28.  Enhancement of (AS  X 
AUG)F1 kidneys transplanted into AS recipients was induced by means of a combined active 
and passive regime by injecting transplant recipients intravenously with 5 ×  107 donor strain 
spleen cells 11 d before kidney transplantation, 1 ml of AS anti-AUG strain antiserum 1 d later, 
and a further 1 ml of the same antiserum at the time of transplantation. 
Survival of AUG kidneys transplanted into AS  recipients was  achieved  by  one  of two 
methods. In some cases, the recipients had previously received an enhanced (AS ×  AUG)F1 
kidney transplanted at least  1 mo previously; the original transplant was then removed and an 
AUG kidney put in its place. Alternatively, the recipients were normal AS rats treated with the 
same enhancing regime as for recipients of (AS ×  AUG)F1 kidneys; in addition, these animals 
were  injected with  cyclophosphamide,  5  mg/kg  per  d  for  14  d.  The  first  dose  was  given 
intravenously at the time of operation, and all subsequent doses were given intraperitoneally. 
At least  1 mo was allowed to elapse before retransplanting the AUG kidneys. 
Serum Ureas.  The glucose creatinine urea analyser 919 (Instrumentation Laboratories Ltd.) 
was used, with an urea enzymatic rate reaction method of 40 ~tl samples. 
Cyclophosphamide.  Cyclophosphamide B.P. (W. B. Pharmaceuticals, Bracknell, England) was 
dissolved immediately before use in sterile distilled water to yield a solution of 20 mg/ml. This 
was  then  diluted  1:10  in  sterile  PBS  and  injected  intravenously or  intraperitoneally as 
appropriate. When the required dosage was 5 mg/kg, the dilution step was 1:20 to reduce error 
in measuring the volume to be injected. 
Induction of Bone Marrow Chimerism.  Strain AS rats bearing a long-surviving  enhanced (AS 
×  AUG)F1  kidney were  given a  lethal  dose  of whole body x  irradiation (1,000  rad).  The 
following day, a monodiscrete suspension of 7 ×  10 7 (AS ×  AUG)FI nucleated bone marrow 
cells was injected intravenously into each irradiated animal. 
In all rats, chimerism was assessed 2 wk later by differential cytotoxicity using an hyperim- 
mune AS  anti-AUG antiserum and  comparing the  degree  of  killing of peripheral  blood 
lymphocytes from a normal AS (background), a normal (AS x  AUG)F1 (positive control), and 
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titer at which 50% specific lysis of their cells was observed was no more than one dilution less 
than observed in the positive control. Retransplantation  of the allogeneic kidneys carried by 
the chimeric AS rats into normal AS secondary recipients was performed shortly after confir- 
mation of the chimerism. 
Results 
Repopulation with Donor Strain Passenger Cells Restores the Immunogenicity of Long-surviving, 
Passively Enhanced Kidney Allografls.  Whereas previous studies on the role of passenger 
cells have involved the injection of suspensions of donor strain cells intravenously or 
intraperitoneally  into  the  recipient  of a  retransplanted  kidney  allograft,  in  this 
experiment  the  immunogenicity  of passenger  cells  in  situ  in  the  graft  was  tested, 
mimicking  more  closely the  constitution  of a  primary  allograft.  The  experimental 
system was to take an intermediate  AS recipient  bearing a  long-surviving, enhanced 
(AS ×  AUG)Fa kidney and render the recipient chimeric by injection of donor strain 
(AS  ×  AUG)F1  bone  marrow  cells.  The  (AS  ×  AUG)Fa  kidneys  of the  chimeric 
intermediate recipients were then retransplanted  into normal AS rats after serological 
confirmation of chimerism.  From Table I, it can be seen that all the animals in this 
group experienced  severe  acute  graft  rejection.  All of them  had  very high  levels of 
serum urea on day  10. Of the five animals,  three died from graft destruction  within 
11 d, a  fourth recipient  (M2) died on day 15 having had a serum urea of>88 mmol/ 
liter on day  10,  and the fifth recipient  M55 survived for 42 d, despite having had a 
serum  urea of 66 mmol/liter  on day  10.  These results  provide confirmation  for the 
hypothesis that  the reduced immunogenicity of retransplanted  kidneys is due to the 
loss of donor strain passenger cells. 
Retransplanted AUG Kidney Allografls Are Rejected.  The  altered  immunogenicity  of 
retransplanted  allografts  is  most  apparent  when  the  outcome  is  indefinite  graft 
survival,  as  occurs in  the  (AS  ×  AUG)Fa  to AS  strain  combination.  Using certain 
strain combinations, however, retransplanted kidneys are rejected, usually at a slightly 
slower tempo and with  minimal  cytotoxic antibody production  (4).  Table II shows 
the  results  in  five AS  rats  given  retransplanted  fully allogeneic  homozygous AUG 
kidney  allografts.  All  the  rats  in  the  group  died  within  the  first  4  wk,  the  median 
survival time being 22 d. Three animals had extremely high serum urea values at  10 
d  (>80 mmol/liter). 
Rejection of Retransplanted AUG Kidney Allografis  Can Be Suppressed with Low Dosage 
Cyclophosphamide.  Our prediction was that the rejection response to a  passenger cell- 
TABLE I 
Survival and Function of (AS × A UG)Ft Kidney Allografis Retransplanted  from Primary as Recipients 
Rendered Chimeric with (AS × AUG)Ft Bone Marrow into Normal Secondary as Strain Recipients 
Serum urea (mmol/liter) 
Rat number  Survival 
Day 0  Day 7  Day 10  Day 14  Day 21  Day 28 
d 
M55  6.9  5.8  66.1  39.1  ND  37.4  42 
M57  9.7  6.4  >88  10 
M59  16.6  6.0  >88  10 
M 1  12.1  8.4  >88  11 
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TABLE  II 
Survival and Function of A UG Kidney Allografls Retransplanted into Secondary as Recipients: 
No Further Treatment 
Serum urea (mmol/liter) 
Rat number  Survival 
Day 0  Day 7  Day 10  Day 14  Day 21  Day 28 
d 
A10  9.8  7.7  24.2  31.6  --  --  16 
A12  8.7  6.9  >83  --  --  --  11 
A17  17.5  11.3  46.3  ND  ND  --  22 
AI8  13.3  8.3  81.5  35.7  48.4  --  22 
A20  21.5  ND  80.9  22.6  21.9  31.6  28 
TABLE  III 
Survival and Function of AUG Kidney Allografis Retransplanted into Secondary as Rectpients Injected with 
Cyclophospharnide from Day 0 to Day 13 
Serum urea (mmol/liter) 
Rat number  Survival 
Day 0  Day 7  Day 10  Day 14  Day 21  Day 28 
d 
A13*  11.5  12.7  33.1  21.2  18.7  10.7  50 
AIS*  11.0  5.8  23.3  22.7  10.0  12.4  90 
A16*  8.3  8.0  13.3  15.3  13.1  8.3  >100 
A21}  9.6  5.9  16.8  83  --  --  15 
A22:~  8.2  7.4  9.8  12.1  8.5  11.2  > 100 
A23~c  9.7  8.9  16.4  10.3  8.6  7.8  > 100 
A40}  7.9  7.4  31.2  30.6  23.6  27.3  35 
* 2.5 mg/kg. 
1.25 mg/kg. 
depleted  allograft,  generated  exclusively via route  2  of alloimmunization,  would  be 
readily suppressed  by small doses of an immunosuppressive  drug. Table  III shows the 
behavior of two  groups  of recipients  treated  with two different  dosages of cyclophos- 
phamide  for the first  14 d  after receiving a  retransplanted  AUG  kidney. All three rats 
treated  with  2.5  mg/kg  per  d  enjoyed  very prolonged  survival,  two  animals  experi- 
enced  a  small  rise  in  serum  urea  at  day  10,  but  by  day  28  all  the  kidneys  were 
functioning  well.  In  the  group  treated  with  1.25  mg/kg,  three  of four  rats  survived 
beyond  1 mo. 
The  Dosage  of Cyclophosphamide  Required  to  Prevent  Rejection  of a  Primary A UG Kidney 
Allograft Is 5×  the Minimum  Dose Effective in Preventing  Rejection of a Retransplanted AUG 
Kidney.  The primary  allograft stimulates  the recipient's immune  response  via routes 
1 and  2,  as  predicted  from  this  hypothesis,  and  the  results  set  out  in  Table  IV show 
that  the minimum  effective dose of cyclophosphamide  in recipients of primary  grafts 
is  substantially  higher  than  that  required  to  prevent  acute  rejection  of the  retran- 
splanted  kidney.  The  animals receiving 2.5 or 5.0 mg/kg  per d  of cyclophosphamide 
cell died from acute graft destruction  within  12 d, as expected for untreated  animals. 
Only when  7.5 mg/kg  was injected was survival prolonged, and  even at  this dose one 
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TABLE IV 
Survival and Function of A UG Kidney Allografls  Transplanted into Primary as Recipients Injected with 
Cyclophosphamide from Day 0 to Day 13 
Serum urea (mmol/liter) 
Rat number  Survival 
Day 7  Day 10  Day 14  Day 21  Day 28 
d 
A  5  *  12.0  :>88  --  --  --  12 
A6*  10.9  :>88  --  --  --  12 
A7*  7.6  :>81  --  --  --  10 
A8*  9.0  >82  --  --  --  10 
A25~:  6.2  >83  --  --  --  10 
A26~:  ND  :>83  --  --  --  10 
A27:~  8.2  76.1  --  --  --  I0 
A28§  6.7  26.8  20.4  11.6  11.4  >60 
A29§  7.2  23.1  82.9  --  --  15 
A37§  6.1  17.5  9.8  14.0  13.0  >43 
A38§  9.0  11.2  9.3  8.8  8.6  >44 
* 2.5 mg/kg. 
:~ 5.0 mg/kg. 
§ 7.5 mg/kg. 
Discussion 
The  experiments  reported here provide additional support  for the passenger cell 
hypothesis and develop further the implication of the two routes of alloimmunization. 
Our  previous  experiments  showed  that  retransplanted  kidney  allografts  devoid  of 
allogeneic passenger cells have  reduced  immunogenicity.  We  now  show  that  if the 
incompatible  passenger  cells are  reintroduced  in  situ,  by  making  the  intermediate 
kidney  graft  recipient  a  chimera  with  donor  strain  bone  marrow  cells,  then  the 
immunogenicity of the retransplanted kidney is restored to the strength characteristic 
of a  normal  primary  allograft.  Given  that  it  has  been  shown  previously that  long 
surviving enhanced  kidneys contain  more  class  I  and  an  equal  amount  of class  II 
alloantigen compared with a  primary allograft (4, 5)  and that  the vascular endothe- 
lium  of such  kidneys carries abundant  class  I  alloantigen  (6),  these  results provide 
conclusive evidence that  the major mechanism  mediating the reduced immunogen- 
icity of the retransplanted  kidney allograft  is  the  depletion of allogeneic passenger 
cells. 
The survival and function of a  retransferred kidney shows some variation, depend- 
ing on the donor recipient combination involved, thus, semi-allogeneic donor kidneys 
fare better than  fully allogeneic grafts. For example, as has already been mentioned, 
(AS X  AUG)F1 kidneys placed in secondary AS recipients function indefinitely, but 
secondary  AS  recipients  of homozygous  AUG  kidneys  die  from  graft  destruction 
usually within 3-4 wk. This presumably results from  the double dose of alloantigen 
carried by the homozygous kidney. There is also some strain variation. In contrast to 
the  slight  rise  in  serum  urea  seen  in  secondary  AS  recipients  of  (AS  ×  AUG)Fi 
kidneys,  six  of  eight  Lewis  recipients  of  retransferred  (DA  X  LEW)Fi  allografts 
experienced very high serum ureas at day 10 and two out of eight animals died at 22 
and 42 d; the others enjoyed indefinite survival (4). This difference between different 
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precursor frequencies of alloreactive cells in the recipients. 
Whether or not graft destruction occurs is only a crude measure of immunogenicity. 
For this reason, a strain combination was chosen in which the retransplanted kidney 
is rejected, thus allowing a  more quantitative measure of immunogenicity. Compari- 
son was made of the dose of cyclophosphamide required to maintain a primary graft, 
immunizing via routes  1 and 2, and a secondary graft immunizing only via route 2. 
The results presented here demonstrate a  fivefold difference in the minimum dosage 
of cyclophosphamide that was needed to prevent effective immunization by the two 
types of graft. 
These results have both conceptual and clinical significance. In addition to provid- 
ing a  quantitative comparison of the relative efficiency of the two routes of alloim- 
munization, they carry the implication that if donor strain APC could be inactivated 
or removed from a human organ allograft, the necessary dosage ofimmunosuppressive 
agents required during the early post-operative phase may be greatly reduced. 
Summary 
It  has been  previously shown  that  long surviving, enhanced  (AS  ×  AUG)F1  rat 
kidneys residing in a primary AS recipient are not acutely rejected if transferred into 
a  second AS recipient. The reduced immunogenicity of the retransplanted  graft was 
attributed to a depletion of incompatible passenger cells. 
It is shown here that if the primary AS recipient is made chimeric by x irradiation 
and  injection  of (AS  ×  AUG)F1 bone marrow cells,  transfer of the  long surviving, 
enhanced graft into a second AS recipient provokes acute graft rejection comparable 
to that observed when normal (AS ×  AUG)F1 kidneys are transplanted into untreated 
AS recipients. 
Transplantation of passenger cell-depleted AUG kidneys into AS recipients leads to 
graft rejection,  with  a  median survival time of 22  d.  Treatment of these  recipients 
with  as  little  as  1.5  mg/kg  cyclophosphamide  for  14  d  induces  prolonged  graft 
survival. By contrast, five times as much cyclophosphamide treatment is required to 
induce  prolonged  survival  of normal  AUG  kidneys  (i.e.,  containing  incompatible 
passenger cells)  transplanted  to AS recipients.  These results confirm that  the major 
alloimmunogenic  stimulus  of  rat  kidney  grafts  is  provided  by  the  incompatible 
passenger cells. 
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